SHARE

Pharmacyte Biotech Inc (OTCMKTS:PMCB) highlighted some of the major objectives that must be met to commence Phase 2b clinical study in pancreatic cancer. The study will assess the safety and effectiveness of company’s pancreatic cancer treatment. This therapy is the combination of microcapsules having genetically modified live cells and low doses of ifosfamide.

Pharmacyte stated that these encapsulated live cells are positioned close to cancerous tumor. It will also release a number of major goals in the coming weeks that will help company first clinical trial to progress. Many of these milestones must be met before a formal IND is submitted with the drug regulatory authorities.

Nutra Pharma Corp. (OTCMKTS:NPHC) reported that the company obtained Orphan Drug designation from the FDA for RPI-78M candidate for Multiple Sclerosis treatment in children. The drug candidate was first derived from cobra venom extract and is a rival of the nicotinic acetylcholine receptor. This medication has an outstandingly low toxicity and has a broad range of uses.

Scientific publications have confirmed that modified and native neurotoxins can safeguard nerve cells from untimely cell death. Furthermore, it is anticipated that RPI-78M may be advantageous in neuromuscular disorders. The technology is covered by patents detailing the use and application of RPI-78M in the cure of autoimmune and viral diseases.

Growblox Sciences Inc (OTCMKTS:GBLX) announced that ex- Nevada Senator Sandra Tiffany will serve the GM of GB Sciences Nevada LLC. In her past role, she held numerous leadership roles and designed key game changing legislation. Ms. Tiffany was a part of legislation when Nevada voters passed the “Medical Marijuana Act.”

She has served on numerous non-profit advisory boards and has been honored in her community. Ms. Tiffany’s possess extensive experience in entrepreneurial business. Before the age of thirty, she formed her first company, known as Computer Methods Inc. in which she marketed and developed a unique structure for nuclear medicine image processing.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY